Sex differences in the temporal dynamics of autistic children’s natural conversations - Molecular Autism

South Africa News News

Sex differences in the temporal dynamics of autistic children’s natural conversations - Molecular Autism
South Africa Latest News,South Africa Headlines
  • 📰 BioMedCentral
  • ⏱ Reading Time:
  • 46 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 22%
  • Publisher: 71%

A study in Molecular Autism finds subtle differences in the speaking patterns of autistic girls and boys and explains why autism is routinely overlooked in girls and women. It proposes better detection and equal treatment facilities for autistic females.

Children had a short, unstructured conversation with a young adult research assistant in a quiet room at the Center for Autism Research, Children’s Hospital of Philadelphia. Confederates were undergraduate students or research assistants who were unaware of participants’ diagnostic status and were assigned to each participant based on scheduling availability.

In addition to duration features, we measured the total number of words produced by participants. We calculated participant speech rate by dividing the total number of words by the sum duration of speech segments plus WT and BT pause duration and multiplying this value by 60. Lastly, we pitch-tracked the audio files using the Robust Algorithm for Pitch Tracking [] with a pitch range of 75–400 Hz and extracted pitch values per 5 ms.

In total, 15 speech features were analyzed in this study: participants’ total speech duration, mean speech segment duration, number of speech segments per minute, total overlap duration, total interrupting duration, total being-interrupted duration, total BT pause duration, mean BT pause duration, number of BT pauses per minute, total WT pause duration, mean WT pause duration, number of WT pauses per minute, total number of words, speech rate, and pitch range.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

BioMedCentral /  🏆 22. in UK

South Africa Latest News, South Africa Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Molecular and network-level mechanisms explaining individual differences in autism spectrum disorder - Nature NeuroscienceMolecular and network-level mechanisms explaining individual differences in autism spectrum disorder - Nature NeuroscienceBuch et al. used machine learning to identify brain–behavior dimensions that define four robust ASD subtypes linked to distinct molecular pathways and that suggest personalized therapeutic targets for circuit-based neuromodulation and pharmacotherapy.
Read more »

Autism: Stalled plans for NI autism job 'hugely frustrating'Autism: Stalled plans for NI autism job 'hugely frustrating''The longer they leave it the worse this crisis is getting,' says the head of an autism charity AutismNIPAPA
Read more »

CAR T-Cell therapy for the management of mantle cell lymphoma - Molecular CancerCAR T-Cell therapy for the management of mantle cell lymphoma - Molecular CancerMantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma (NHL) of mature B-cells characterized by translocation, which is typically due to excess expression of Cyclin D1. Although with the progress in our knowledge of the causes for MCL and available treatments for MCL, this cancer is still incurable. Age, male gender, rapid advancement, significant nodal involvement, elevated serum lactate dehydrogenase level, and prognostic indications including increased expression of Ki-67 and presence of TP53 mutation, are symbols of poor outcome. Advanced immunotherapy using chimeric antigen receptor (CAR)-T cells is advantageous for patients suffering from B-cell malignancies and MCL. Targeting B-cell antigens on the cell surface is a feasible approach in re-occurring (R/R) MCL because of significant responses obtained in other B-cell cancers. USFDA has approved brexucabtagene autoleucel (Tecartus, KTE-X19), a novel CAR T-cell therapy to be used in patients with MCL who have not responded to previous treatments or have relapsed. The FDA approved this new treatment depending on the outcomes of the ZUMA-2 clinical trial. Serious adverse reactions, moderate anti-tumor activity, allergen withdrawal, antigen escape, limited tumor infiltration, and trafficking are major barriers to successful CAR T-cell therapy. This review is a brief synopsis of the development of CAR T-cell therapy for MCL.
Read more »

Dedicated Molecular Nanocages for siRNA DeliveryDedicated Molecular Nanocages for siRNA DeliveryThe innovative therapies known as small interfering RNAs (siRNAs) can be utilized to treat a variety of diseases.
Read more »

“Autism made me feel like an alien, but now I see it as a superpower”“Autism made me feel like an alien, but now I see it as a superpower”'I felt like I was an alien who had crash-landed on another planet, desperately wondering why I couldn’t just fit in, why what made sense to others didn’t to me.”
Read more »

Milder Autism Is Rising Far Faster Than the More Severe Type, Study SaysMilder Autism Is Rising Far Faster Than the More Severe Type, Study SaysA new study shows the rate of “profound” autism is rising, but not as quickly as milder autism
Read more »



Render Time: 2025-02-28 17:53:47